Genetic engineering of live rabies vaccines.
Publication/Presentation Date
5-14-2001
Abstract
Rabies virus is not a single entity but consists of a wide array of variants that are each associated with different host species. These viruses differ greatly in the antigenic makeup of their G proteins, the primary determinant of pathogenicity and major inducer of protective immunity. Due to this diversity, existing rabies vaccines have largely been targeted to individual animal species. In this report, a novel approach to the development of rabies vaccines using genetically modified, reverse-engineered live attenuated rabies viruses is described. This approach entails the engineering of vaccine rabies virus containing G proteins from virulent strains and modification of the G protein to further reduce pathogenicity. Strategies employed included exchange of the arginine at position 333 for glutamine and modification of the cytoplasmic domain. The recombinant viruses obtained were non-neuroinvasive when administered via a peripheral route. The ability to confer protective immunity depended largely upon conservation of the G protein antigenic structure between the vaccine and challenge virus, as well as on the route of immunization.
Volume
19
Issue
25-26
First Page
3543
Last Page
3551
ISSN
0264-410X
Published In/Presented At
Morimoto, K., McGettigan, J. P., Foley, H. D., Hooper, D. C., Dietzschold, B., & Schnell, M. J. (2001). Genetic engineering of live rabies vaccines. Vaccine, 19(25-26), 3543–3551. https://doi.org/10.1016/s0264-410x(01)00064-0
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
11348722
Department(s)
Administration and Leadership
Document Type
Article